Body habitus in heart failure: Understanding the mechanisms and clinical significance of the obesity paradox

Future Cardiology

Volumn 12, Issue 6, 2016, Pages 639-653

  Parto, Parham ^a   Lavie, Carl J ^a   Arena, Ross ^b   Bond, Samantha ^b   Popovic, Dejana ^c   Ventura, Hector O ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

BMI; Body habitus; Cardiorespiratory fitness; Gender; Heart failure; HTN; Obesity; Obesity paradox; Weight loss

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GHRELIN; LEPTIN; LIPOPROTEIN; RESISTIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADIPOSE TISSUE; ATRIAL FIBRILLATION; BODY BUILD; BODY MASS; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DEVICE THERAPY; DISEASE ASSOCIATION; HEART ATRIUM ENLARGEMENT; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART RIGHT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; HEART TRANSPLANTATION; HORMONE ACTION; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SEX DIFFERENCE; UPREGULATION; WEIGHT REDUCTION; ADOLESCENT; ADULT; BODY WEIGHT LOSS; CHILD; COMPLICATION; FEMALE; MALE; SEX FACTOR;

ADOLESCENT; ADULT; BODY MASS INDEX; CHILD; FEMALE; HEART FAILURE; HUMANS; MALE; OBESITY; PROGNOSIS; RISK FACTORS; SEX FACTORS; WEIGHT LOSS;

EID: 84994667585     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca-2016-0029     Document Type: Review

References (125)

1. WHO. Obesity: preventing and managing the global epidemic. In: World Health Organization Technical Report 894. WHO, Geneva, Switzerland (2000).
2. Clark AL, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Prog. Cardiovasc. Dis. 56, 409-414 (2014).
3. Fryar C, Carroll M, Ogden C. Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1960-1962 through 2009-2010. National Center for Health Statistics. 1-8 (2012). www.cdc.gov.
4. Stevens GA, Singh GM, Lu Y et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul. Health Metr. 10(1), 22 (2012).
5. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief (82), 1-8 (2012).
6. Apovian CM. The obesity epidemic - understanding the disease and the treatment. N. Engl. J. Med. 374(2), 177-179 (2016).
7. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 1(2), 93-102 (2013).
8. Bastien M, Poirier P, Lemieux I, Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog. Cardiovasc. Dis. 56(4), 369- 381 (2014).
9. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease. risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 53(21), 1925-1932 (2009).
10. Lavie CJ, Ventura HO. The obesity paradox in heart failure. J. Am. Coll. Cardiol. 3(11), 927-930 (2015).
11. Sharma A, Lavie C, Borer J et al. Meta-Analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am. J. Cardiol. 115(10), 1428-1434 (2015).
12. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J. Am. Coll. Cardiol. 63(14), 1345-1354 (2014).
13. Alexander J, Alpert M. Hemodynamic alterations with obesity in man. In: The Heart and Lung in Obesity. Alexander J, Alpert M (Eds). Futura Publishing Company, NY, USA, 45-46 (1998).
14. Alexander J. Obesity and cardiac performance. Am. J. Cardiol. 14(6), 860-865 (1964).
15. Alexander J, Dennis E, Smith W, Amad K, Duncan W, Austin R. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc. Res. Cent. Bull. 1(Winter), 39-44 (1962).
16. Alpert MA, Omran J, Mehra A, Ardhanari S. Impact of obesity and weight loss on cardiac performance and morphology in adults. Prog. Cardiovasc. Dis. 56(4), 391-400 (2014).
17. Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: Epidemiology, pathophysiology, clinical manifestations, and management. Transl. Res. 164(4), 345-356 (2014).
18. Bella JN, Devereux RB, Roman MJ et al. Relations of left ventricular mass to fat-free and adipose body mass : The strong heart study. Circulation 98(23), 2538-2544 (1998).
19. Neeland IJ, Gupta S, Ayers CR et al. Relation of regional fat distribution to left ventricular structure and function. Circ. Cardiovasc. Imaging 6(5), 800-807 (2013).
20. Patel DA, Lavie CJ, Milani RV, Gilliland Y, Shah S, Ventura HO. Association of left ventricular geometry with left atrial enlargement in patients with preserved ejection fraction. Congest. Heart Fail. 18(1), 4-8 (2012).
21. Lauer M, Anderson K, Kannel W, Levy D. The impact of obesity on left ventricular mass and geometry: The Framingham Heart Study. JAMA 266(2), 231-236 (1991).
22. Alpert M, Alexander J. Cardiac morphology and obesity in man. In: The Heart And Lung in Obesity. Alpert M, Alexander J (Eds). Futura Publishing Company, NY, USA, 25-44 (1998).
23. Alpert M, Terry B, Kelly D. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. Am. J. Cardiol. 55(6), 783-786 (1985).
24. Pascual M. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart 89(10), 1152-1156 (2003).
25. Russo C, Jin Z, Homma S et al. Effect of obesity and overweight on left ventricular diastolic function: A community-based study in an elderly cohort. J. Am. Coll. Cardiol. 57(12), 1368-1374 (2011).
26. Brassard P, Legault S, Garneau C, Bogaty P, Dumesnil J-G, Poirier P. Normalization of diastolic dysfunction in Type 2 diabetics after exercise training. Med. Sci. Sports Exerc. 39(11), 1896-1901 (2007).
27. Martin J, Bergeron S, Pibarot P et al. Impact of bariatric surgery on N-Terminal fragment of the prohormone brain natriuretic peptide and left ventricular diastolic function. Can. J. Cardiol. 29(8), 969-975 (2013).
28. Alpert M, Alexander J, Chakko S. Obesity and ventricular function in man: systolic function. In: The Heart and Lung in Obesity. Alpert M, Alexander J (Eds). Futura Publishing Company, NY, USA, 77-94 (1998).
29. Alpert M. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am. J. Med. Sci. 321(4), 225-236 (2001).
30. Alpert M, Terry B, Lambert C et al. Factors influencing left ventricular systolic function in nonhypertensive morbidly obese patients, and effect of weight loss induced by gastroplasty. Am. J. Cardiol. 71(8), 733-737 (1993).
31. Alpert M, Singh A, Terry B, Kelly D, Villarreal D, Mukerji V. Effect of exercise on left ventricular systolic function and reserve in morbid obesity. Am. J. Cardiol. 63(20), 1478-1482 (1989).
32. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 110(19), 3081-3087 (2004).
33. Lavie CJ, Sharma A, Alpert MA et al. Update on obesity and obesity paradox in heart failure. Prog. Cardiovasc. Dis. 58(4), 393-400 (2015).
34. Kenchaiah S, Evans J. Obesity and the risk of heart failure. N. Engl. J. Med. 347, 305-313 (2002).
35. Hu G, Jousilahti P, Antikainen R, Katzmarzyk PT, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-To-hip ratio on the risk of heart failure. Circulation 121(2), 237-244 (2010).
36. Vest AR, Wu Y, Hachamovitch R, Young JB, Cho L. The heart failure overweight/obesity survival paradox: The missing sex link. JACC Heart Fail. 3(11), 917-926 (2015).
37. Peterson LR, Soto PF, Herrero P et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc. Imaging 1(4), 424-433 (2008).
38. O'Meara E, Clayton T, McEntegart MB et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Circulation 115(24), 3111-3120 (2007).
39. Ghali JK, Krause-Steinrauf HJ, Adams KF et al. Gender differences in advanced heart failure: insights from the BEST study. J. Am. Coll. Cardiol. 42(12), 2128-2134 (2003).
40. Mittendorfer B. Sexual dimorphism in human lipid metabolism. J. Nutr. 135(4), 681-686 (2005).
41. Lavie C, Osman A, Milani R, Mehra M. Body composition and prognosis in chronic systolic heart failure: The obesity paradox. Am. J. Cardiol. 91(7), 891-894 (2003).
42. Menzaghi C, Xu M, Salvemini L et al. Circulating adiponectin and cardiovascular mortality in patients with Type 2 diabetes mellitus: Evidence of sexual dimorphism. Cardiovasc. Diabetol. 13(1), 130 (2014).
43. Hall M, do Carmo J, da Silva A, Juncos L, Wang Z, Hall J. Obesity, hypertension, and chronic kidney disease. Int. J. Nephrol. Renov. Dis. 7, 75-88 (2014).
44. Hall JE, da Silva AA, do Carmo JM et al. Obesity-induced hypertension: Role of sympathetic nervous system, leptin, and melanocortins. J. Biol. Chem. 285(23), 17271-17276 (2010).
45. Messerli FH, Sundgaard-Riise K, Reisin ED et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann. Intern Med. 99(6), 757 (1983).
46. Messerli FH, Sundgaard-Riise K, Reisin E, Dreslinski G, Dunn FG, Frohlich E. Disparate cardiovascular effects of obesity and arterial hypertension. Am. J. Med. 74(5), 808-812 (1983).
47. Aurigemma GP, de Simone G, Fitzgibbons TP. Cardiac remodeling in obesity. Circ. Cardiovasc. Imaging 6(1), 142-52 (2013).
48. Woodiwiss AJ, Libhaber CD, Majane OHI, Libhaber E, Maseko M, Norton GR. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am. J. Hypertens. 21(10), 1144-1151 (2008).
49. Lavie CJ, Milani RV, Patel D, Artham SM, Ventura HO. Disparate effects of obesity and left ventricular geometry on mortality in 8088 elderly patients with preserved systolic function. Postgrad. Med. 121(3), 119-125 (2015).
50. Peterson LR, Waggoner AD, Schechtman KB et al. Alterations in left ventricular structure and function in young healthy obese women: Assessment by echocardiography and tissue Doppler imaging. J. Am. Coll. Cardiol. 43(8), 1399-1404 (2004).
51. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J. Am. Coll. Cardiol. 30(4), 1039-1045 (1997).
52. Rabah A, Wazni O. Atrial fibrillation in heart failure: catheter and surgical interventional therapies. Heart Fail. Rev. 19(3), 325-330 (2014).
53. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J. Am. Coll. Cardiol. 29(4), 709-715 (1997).
54. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity-results of a meta-Analysis. Am. Heart J. 155(2), 310-315 (2008).
55. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 107(23), 2920-2925 (2003).
56. Benjamin E, Levy D, Vaziri S, D'Agostino R, Belanger A, Wolf P. Independent risk factors for atrial fibrillation in a population-based cohort. JAMA 271(11), 840 (1994).
57. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am. J. Cardiol. 91(6), 2-8 (2003).
58. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 38(3), 789-795 (2001).
59. Clark AL, Chyu J, Horwich TB. The obesity paradox in men versus women with systolic heart failure. Am. J. Cardiol. 110(1), 77-82 (2012).
60. Khalid U, Ather S, Bavishi C et al. Pre-morbid body mass index and mortality after incident heart failure: The ARIC Study. J. Am. Coll. Cardiol. 64(25), 2743-2749 (2014).
61. Das SR, Alexander KP, Chen AY et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50, 149 patients with ST-segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J. Am. Coll. Cardiol. 58(25), 2642-2650 (2011).
62. Shah R, Gayat E, Januzzi JL et al. Body mass index and mortality in acutely decompensated heart failure across the world. J. Am. Coll. Cardiol. 63(8), 778-785 (2014).
63. Mørkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. J. Am. Coll. Cardiol. 63(11), 1071-1078 (2014).
64. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: A meta-Analysis. Am. Heart J. 156(1), 13-22 (2008).
65. Anker SD, Negassa A, Coats AJS et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet 361(9363), 1077-1083 (2003).
66. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J. Am. Coll. Cardiol. 43(8), 1439-1444 (2004).
67. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JMP, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am. J. Physiol. Endocrinol. Metab. 277(6), e971-e975 (1999).
68. Sandek A, Utchill S, Rauchhaus M. The endotoxin-lipoprotein hypothesis -An update. Arch. Med. Sci. 3(4A), S81 (2007).
69. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol. Rev. 88(2), 389-419 (2008).
70. Seven E. Overweight, hypertension and cardiovascular disease: focus on adipocytokines, insulin, weight changes and natriuretic peptides. Dan. Med. J. 62(11), B5163 (2015).
71. Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10(12), 1384-1389 (2004).
72. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc. Med. 16(5), 141-146 (2006).
73. Srikanthan K, Feyh A, Visweshwar H, Shapiro J, Sodhi K. Systematic review of metabolic syndrome biomarkers: A panel for early detection, management, and risk stratification in the West Virginian population. Int. J. Med. Sci. 13(1), 25-38 (2016).
74. Luo J-D, Zhang G-S, Chen M-S. Leptin and cardiovascular diseases. Timely Top. Med. Cardiovasc. Dis. 9, E34 (2005).
75. Mark AL, Correia MLG, Rahmouni K, Haynes WG. Loss of leptin actions in obesity: Two concepts with cardiovascular implications. Clin. Exp. Hypertens. 26(7-8), 629-636 (2004).
76. Hall ME, Harmancey R, Stec DE. Lean heart: Role of leptin in cardiac hypertrophy and metabolism. World J. Cardiol. 7(9), 511-524 (2015).
77. Badoer E, Kosari S, Stebbing MJ. Resistin, an adipokine with non-generalized actions on sympathetic nerve activity. Front. Physiol. 6, 321 (2015).
78. Khatib MN, Simkhada P, Gode D. Cardioprotective effects of ghrelin in heart failure: from gut to heart. Heart Views 15(3), 74-76 (2014).
79. Zhang G-G, Cai H-Q, Li Y-H et al. Ghrelin protects heart against ERS-induced injury and apoptosis by activating AMP-Activated protein kinase. Peptides 48, 156-165 (2013).
80. Yano Y, Nakazato M, Toshinai K et al. Circulating des-Acyl ghrelin improves cardiovascular risk prediction in older hypertensive patients. Am. J. Hypertens. 27(5), 727-733 (2014).
81. Yang C, Liu Z, Liu K, Yang P. Mechanisms of Ghrelin anti-heart failure: inhibition of Ang II-induced cardiomyocyte apoptosis by down-regulating AT1R expression. PLoS ONE 9(1), e85785 (2014).
82. Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc. Natl Acad. Sci. USA 107(6), 2604-2609 (2010).
83. Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm. IGF Res. 25(2), 59-65 (2015).
84. Karastergiou K, Fried SK. Multiple adipose depots increase cardiovascular risk via local and systemic effects. Curr. Atheroscler. Rep. 15(10), 361 (2013).
85. do Carmo J, da Silva A, Wang Z et al. Regulation of blood pressure, appetite, and glucose by leptin after inactivation of insulin receptor substrate 2 signaling in the entire brain or in proopiomelanocortin neurons. Hypertension 67(2), 378-386 (2016).
86. Leal-Cerro A, Soto A, Martínez MA, Dieguez C, Casanueva FF. Influence of cortisol status on leptin secretion. Pituitary 4(1-2), 111-116.
87. Amir O, Sagiv M, Eynon N et al. The response of circulating brain natriuretic peptide to academic stress in college students. Stress 13(1), 83-90 (2010).
88. Mehra MR, Uber PA, Park MH et al. Obesity and suppressed B-Type natriuretic peptide levels in heart failure. J. Am. Coll. Cardiol. 43(9), 1590-1595 (2004).
89. Ndumele CE, Matsushita K, Sang Y et al. NT-proBNP and Heart Failure Risk Among Individuals With and Without Obesity: The ARIC Study. Circulation 133(7), 631-638 (2016).
90. Das SR, Drazner MH, Dries DL et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: Results from the Dallas Heart Study. Circulation 112(14), 2163-218 (2005).
91. Zavin A, Daniels K, Arena R et al. Adiposity facilitates increased strength capacity in heart failure patients with reduced ejection fraction. Int. J. Cardiol. 167(6), 2468-2471 (2013).
92. Lavie CJ, De Schutter A, Patel DA, Romero-Corral A, Artham SM, Milani RV. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the "obesity paradox". J. Am. Coll. Cardiol. 60(15), 1374-1380 (2012).
93. Artero EG, Lee D, Lavie CJ et al. Effects of muscular strength on cardiovascular risk factors and prognosis. J. Cardiopulm. Rehabil. Prev. 32(6), 351-358 (2012).
94. Arena R, Lavie CJ. The obesity paradox and outcome in heart failure: is excess bodyweight truly protective? Future Cardiol. 6(1), 1-6 (2010).
95. Kodama S. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women. JAMA 301(19), 2024 (2009).
96. Lee D-C, Sui X, Ortega FB et al. Comparisons of leisure-Time physical activity and cardiorespiratory fitness as predictors of all-cause mortality in men and women. Br. J. Sports Med. 45(6), 504-510 (2011).
97. Kaminsky LA, Arena R, Beckie TM et al. The importance of cardiorespiratory fitness in the United States: The need for a national registry: A policy statement from the American Heart Association. Circulation 127(5), 652-662 (2013).
98. Artero EG, Lee D, Ruiz JR et al. A prospective study of muscular strength and all-cause mortality in men with hypertension. J. Am. Coll. Cardiol. 57(18), 1831-1837 (2011).
99. Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. fatness on all-cause mortality: A meta-Analysis. Prog. Cardiovasc. Dis. 56(4), 382-390 (2014).
100. Gupta S, Rohatgi A, Ayers CR et al. Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. Circulation 123(13), 1377-1383 (2011).
101. Lee D-C, Sui X, Church TS, Lavie CJ, Jackson AS, Blair SN. Changes in fitness and fatness on the development of cardiovascular disease risk factors hypertension, metabolic syndrome, and hypercholesterolemia. J. Am. Coll. Cardiol. 59(7), 665-672 (2012).
102. Lee D, Sui X, Artero EG et al. Long-Term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: The Aerobics Center Longitudinal Study. Circulation 124(23), 2483-2490 (2011).
103. Parto P, Lavie C, Arena R, Ventura H. Preventing heart failure with exercise training. Curr. Cardiovasc. Risk Rep. 9(9), doi:10.1007/s12170-015-0472-3 (2015) (Epub ahead of print).
104. Lavie CJ, Cahalin LP, Chase P et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin. Proc. 88(3), 251-258 (2013).
105. Clark AL, Fonarow GC, Horwich TB. Impact of cardiorespiratory fitness on the obesity paradox in patients with systolic heart failure. Am. J. Cardiol. 115(2), 209-213 (2015).
106. Uretsky S, Supariwala A, Gurram S et al. The interaction of exercise ability and body mass index upon long-Term outcomes among patients undergoing stress-rest perfusion single-photon emission computed tomography imaging. Am. Heart J. 166(1), 127-133 (2013).
107. Allison D, Zannolli R, Faith M et al. Weight loss increases and fat loss decreases all-cause mortality rate: Results from two independent cohort studies. Int. J. Obes. 23(6), 603-611 (1999).
108. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393-403 (2002).
109. Tuomilehto J, Lindström J, Eriksson J et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343-1350 (2001).
110. Milani R, Lavie C. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac. Am. J. Cardiol. 92(1), 50-54 (2003).
111. Lavie CJ, Milani RV, Artham SM, Patel DA, Ventura HO. The obesity paradox, weight loss, and coronary disease. Am. J. Med. 122(12), 1106-1114 (2009).
112. Rider OJ, Francis JM, Ali MK et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J. Am. Coll. Cardiol. 54(8), 718-726 (2009).
113. Hsuan C-F, Huang C-K, Lin J-W et al. The effect of surgical weight reduction on left ventricular structure and function in severe obesity. Obesity (Silver Spring) 18(6), 1188-1193 (2010).
114. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16), e240-e327 (2013).
115. Slaughter MS, Pagani FD, Rogers JG et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J. Heart Lung Transplant. 29(Suppl. 4), S1-S39 (2010).
116. Mano A, Fujita K, Uenomachi K et al. Body mass index is a useful predictor of prognosis after left ventricular assist system implantation. J. Heart Lung Transplant. 28(5), 428-433 (2009).
117. Lockard K, Degore L, Schwarm P. Lack of improvement in prealbumin at two weeks predicts a poor outcome after mechanical circulatory support. J. Heart Lung Transplant. 28(2), S66 (2009).
118. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int. J. Obes. 37(3), 333-340 (2013).
119. Lietz K, John R, Burke E et al. Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation. Transplantation 72(2), 277-283 (2001).
120. Grady KL, White-Williams C, Naftel D et al. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: A multi-institutional study of erative weight-height indices. J. Heart Lung Transplant. 18(8), 750-763 (1999).
121. Trulock E, Edwards L, Taylor D, Boucek M, Keck B, Hertz M. The Registry of the International Society for Heart and Lung Transplantation: Twenty-first official adult lung and heart-lung transplant report - 2004. J. Heart Lung Transplant. 23(7), 804-815 (2004).
122. Weiss ES, Allen JG, Russell SD, Shah AS, Conte JV. Impact of recipient body mass index on organ allocation and mortality in orthotopic heart transplantation. J. Heart Lung Transplant. 28(11), 1150-1157 (2009).
123. Mehra M, Kobashigawa J, Starling R et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates. J. Heart Lung Transplant. 25(9), 1024-1042 (2006).
124. Wikiel KJ, McCloskey CA, Ramanathan RC. Bariatric surgery: A safe and effective conduit to cardiac transplantation. Surg. Obes. Relat. Dis. 10(3), 479-484 (2014).
125. Chaudhry UI, Kanji A, Sai-Sudhakar CB, Higgins RS, Needleman BJ. Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart failure and left ventricular assist device: medium-Term results. Surg. Obes. Relat. Dis. 11(1), 88-93 (2015).